---
title: "TCGX appoints Joshua Cohen and Mark McKenna; Dr. Michael Henderson joins board"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302329228.md"
description: "TCGX appointed Joshua Cohen, Mark McKenna, and Dr. Michael Henderson to its board effective October 15, 2026, in connection with its IPO. Cohen and McKenna serve as Class I and II directors, while Henderson is a Class III director. Committee roles include Henderson as Audit Committee chair and McKenna as Compensation Committee chair. This appointment coincides with the resignation of Chen Yu and Craig Skaling upon IPO completion."
datetime: "2026-10-19T21:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302329228.md)
  - [en](https://longbridge.com/en/news/302329228.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302329228.md)
generator: "portal-rs"
---

# TCGX appoints Joshua Cohen and Mark McKenna; Dr. Michael Henderson joins board

**TCGX appointed Joshua Cohen, Mark McKenna and Dr. Michael Henderson to its board, with committee roles assigned including Dr. Henderson as Audit Committee chair and Mr. McKenna as Compensation Committee chair.**

Individual

Joshua Cohen

Mark McKenna

Dr. Michael Henderson

Role

Director; Class I

Director; Class II

Director; Class III

Type of Change

Appointed

Appointed

Appointed

Effective Date

October 15, 2026

October 15, 2026

October 15, 2026

Reason

In connection with IPO

In connection with IPO

In connection with IPO

Replacement Info

Chen Yu and Craig Skaling resigned upon IPO completion

Chen Yu and Craig Skaling resigned upon IPO completion

Chen Yu and Craig Skaling resigned upon IPO completion

Background Details

Independent director (per filing)

Independent director (per filing)

Independent director; M.D. (per filing)

Board/Committee Role Changes

Appointed to Audit and Compensation Committees

Appointed to Audit and Compensation Committees; Chair of Compensation Committee

Appointed to Audit and Compensation Committees; Chair of Audit Committee

Original SEC Filing: TCGX Acquisition Corp. II \[ TCXB \] - 8-K - Oct. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TCGX.US](https://longbridge.com/en/quote/TCGX.US.md)
- [TCXB.US](https://longbridge.com/en/quote/TCXB.US.md)

## Related News & Research

- [TCGX Acquisition II Files Initial Beneficial Ownership Statement for Director Joshua B. Cohen](https://longbridge.com/en/news/302467224.md)
- [TCGX Acquisition to Combine With TriGemX in SPAC Deal Valued at $361M, With $160M PIPE](https://longbridge.com/en/news/302295761.md)
- [TCGX Acquisition agrees to combine with TriGemX Bio](https://longbridge.com/en/news/302278483.md)
- [TCGX Acquisition net loss totals $67,614 for quarter ended June 30, 2026](https://longbridge.com/en/news/298639048.md)
- [Vaderis Therapeutics raises $152 million in Series B financing](https://longbridge.com/en/news/295667421.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**